BioCentury
ARTICLE | Company News

Prima BioMed, Austin Research Institute deal

August 15, 2005 7:00 AM UTC

PRR proposed to acquire the institute's share and option holdings in four PRR subsidiaries for 15 million shares. The deal would be valued at A$1.7 million ($1.3 million) based on PRR's close of A$0.12 on Aug. 8, before the deal was announced, and the institute would have close to a 10% share in PRR. The subsidiaries are Oncomab Pty Ltd., Panvax Ltd., Cancer Vac Pty Ltd. and Arthron Pty Ltd. ...